As we have also seen above, CBD is considered to have wider applications than THC. Since CBD has been much less studied than THC, scientists assume that there are many new applications of CBD that haven’t yet been discovered. On the other hand, THC’s applications are more or less completely explored by now due to all the research on medical marijuana over the past decade.
Similar to energy drinks and protein bars which may contain vitamin or herbal additives, food and beverage items can be infused with CBD as an alternative means of ingesting the substance. In the United States, numerous products are marketed as containing CBD, but in reality contain little or none. Some companies marketing CBD-infused food products with claims that are similar to the effects of prescription drugs have received warning letters from the Food and Drug Administration for making unsubstantiated health claims. In February 2019, the New York City Department of Health announced plans to fine restaurants that sell food or drinks containing CBD, beginning in October 2019.
Food and beverage products containing CBD were introduced in the United States in 2017.[dubious – discuss] Hemp seed ingredients which do not naturally contain THC or CBD (but which may be contaminated with trace amounts on the outside during harvesting) were declared by the FDA as GRAS in December 2018. CBD itself has not been declared GRAS, and under U.S. federal law is illegal to sell as a food, dietary supplement, or animal feed. State laws vary considerably as non-medical cannabis and derived products have been legalized in some jurisdictions in the 2010s.
Perhaps the most enjoyable way to take CBD is through CBD edibles. CBD edibles are food products that have been infused with hemp-derived CBD. Generally, CBD edibles contain a lower serving, usually 5 to 10 mg of CBD each, allowing you to easily increase or decrease your intake based on your individual wellness needs. CBD edibles come in the form of delicious CBD gummies and bite-sized CBD energy chews.
Schizophrenia. Research on the use of cannabidiol for psychotic symptoms in people with schizophrenia is conflicting. Some early research suggests that taking cannabidiol four times daily for 4 weeks improves psychotic symptoms and might be as effective as the antipsychotic medication amisulpride. However, other early research suggests that taking cannabidiol for 14 days is not beneficial. The conflicting results might be related to the cannabidiol dose used and duration of treatment.
It is because hemp only recently became legal to grow in the U.S. that many of the finished hemp goods that you see for sale in America, from food products to clothing to building materials, are part of an imported hemp industry that has surpassed $688 million annually. The size of this import industry was one of the major catalysts for hemp legalization in the U.S. As a renewable source of a range of products, hemp provides an exciting new step in American agriculture.
Cannabidiol is insoluble in water but soluble in organic solvents such as pentane. At room temperature, it is a colorless crystalline solid. In strongly basic media and the presence of air, it is oxidized to a quinone. Under acidic conditions it cyclizes to THC, which also occurs during pyrolysis (smoking). The synthesis of cannabidiol has been accomplished by several research groups.
Cannabidiol has low affinity for the cannabinoid CB1 and CB2 receptors, although it can act as an antagonist of CB1/CB2 agonists despite this low affinity. Cannabidiol may be an antagonist of GPR55, a G protein-coupled receptor and putative cannabinoid receptor that is expressed in the caudate nucleus and putamen in the brain. It also may act as an inverse agonist of GPR3, GPR6, and GPR12. CBD has been shown to act as a serotonin 5-HT1A receptor partial agonist. It is an allosteric modulator of the μ- and δ-opioid receptors as well. The pharmacological effects of CBD may involve PPARγ agonism and intracellular calcium release.
CBD does not appear to have any psychotropic ("high") effects such as those caused by ∆9-THC in marijuana, but may have anti-anxiety and anti-psychotic effects. As the legal landscape and understanding about the differences in medical cannabinoids unfolds, experts are working to distinguish "medical marijuana" (with varying degrees of psychotropic effects and deficits in executive function) – from "medical CBD therapies” which would commonly present as having a reduced or non-psychoactive side-effect profile.
^ Nadulski T, Pragst F, Weinberg G, Roser P, Schnelle M, Fronk EM, Stadelmann AM (December 2005). "Randomized, double-blind, placebo-controlled study about the effects of cannabidiol (CBD) on the pharmacokinetics of Delta9-tetrahydrocannabinol (THC) after oral application of THC verses standardized cannabis extract". Ther Drug Monit. 27 (6): 799–810. doi:10.1097/01.ftd.0000177223.19294.5c. PMID 16306858.
Selective breeding of cannabis plants has expanded and diversified as commercial and therapeutic markets develop. Some growers in the US succeeded in lowering the proportion of CBD-to-THC to accommodate customers who preferred varietals that were more mind-altering due to the higher THC and lower CBD content. In the US, hemp is classified by the federal government as cannabis containing no more than 0.3% THC by dry weight. This classification was established in the 2018 Farm Bill and was refined to include hemp-sourced extracts, cannabinoids, and derivatives in the definition of hemp.
In September 2018, following its approval by the FDA for rare types of childhood epilepsy, Epidiolex was rescheduled (by the Drug Enforcement Administration) as a Schedule V drug to allow for its prescription use. This allows GW Pharmaceuticals to sell Epidiolex, but it does not apply broadly and all other CBD-containing products remain Schedule I drugs. Epidiolex still requires rescheduling in some states before it can be prescribed in those states.
Multiple sclerosis (MS). A prescription-only nasal spray product (Sativex, GW Pharmaceuticals) containing both 9-delta-tetrahydrocannabinol (THC) and cannabidiol has been shown to be effective for improving pain, muscle-tightness, and urination frequency in people with MS. This product is used in over 25 countries outside of the United States. But there is inconsistent evidence on the effectiveness of cannabidiol for symptoms of multiple sclerosis when it is used alone. Some early research suggests that using a cannabidiol spray under the tongue might improve pain and muscle tightness, but not muscle spasms, tiredness, bladder control, mobility, or well-being and quality of life in patients with MS.
Industrial hemp is produced by strains of Cannabis sativa that have been cultivated to produce minimal levels of THC and are instead artificially selected and bred to grow taller and sturdier. This is done to enable the plant to be used effectively in the production of hemp oil, wax, resin, hemp seed food, animal feed, fuel, cloth, rope, and more. Industrial hemp is exclusively made from Cannabis sativa.
It’s complicated. State laws regulating the sale, production and possession of CBD oil widely vary, and many states allow some form of CBD. If passed, new provisions in this year’s Farm Bill would legalize industrial hemp and could make hemp-derived CBD oil legal in all 50 states. But be aware that except for an FDA-approved medication for childhood epilepsy, the Federal Drug Enforcement Administration still maintains that CBD is illegal.